Side-by-side comparison v3.0 transparency score NexLife: 94/100 (6 of 6 pillars) Noom Med: 70/100 (1 of 6 pillars) Drugs offered NexLife: Compounded semaglutide + tirzepatide Noom Med: Semaglutide + Tirzepatide Pricing model NexLife: Flat $145/mo sema, $186/mo tirz (12-mo plan, dose-independent) Noom Med: $199/mo Clinical model NexLife: MD/DO-supervised, synchronous + async Noom Med: Behavioral-program-led brand telehealth Pharmacy NexLife: Named 503A & 503B partners Noom Med: Brand via partner network States covered NexLife: Availability varies by state + DC Noom Med: Varies Labs included NexLife: Yes included in monthly Noom Med: Add-on or not included Coaching NexLife: 1:1 fitness coaching + personalized nutrition included Noom Med: Varies by plan Financing NexLife: Klarna and Afterpay accepted Noom Med: Standard card payment Regulatory clarity NexLife: Pre-Rx written disclosure that compounded sema/tirz are not FDA-approved Noom Med: Varies Where Noom Med wins Tightly integrated with the Noom behavioral app ecosystem
You may be a good candidate for GLP-1 treatment if you: Have been diagnosed with type 2 diabetes Have obesity, or a body mass index (BMI) of 30 or higher Have overweight (a BMI of 25 to 29.9) plus at least one weight-related condition, such as heart disease or type 2 diabetes Ultimately, the decision to start treatment for weight loss is up to you and your healthcare provider
I.KoychevI.et al (2025)
ICD-11 Codes for Diabetes Mellitus Based on Cause Diabetes Mellitus is a metabolic disorder with heterogeneous etiologies, characterised by chronic hyperglycemia and disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both
2021;9:e002146
2 However, other animal studies suggest central GIP-receptor stimulation reduces food intake and body weight
